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Infections with human rhinovirus (HRV) are commonly associated with acute upper
and lower respiratory tract disease and asthma exacerbations. The role that HRVs
play in these diseases suggests it is important to understand host-specific or virus-
specific factors that contribute to pathogenesis. Since species A HRVs are often
associated with more serious HRV disease than species B HRVs, differences in
immune responses they induce should inform disease pathogenesis. To identify
species differences in induced responses, we evaluated 3 species A viruses, HRV
25, 31 and 36 and 3 species B viruses, HRV 4, 35 and 48 by exposing human
PBMCs to HRV infected Calu-3 cells. To evaluate the potential effect of memory
induced by previous HRV infection on study responses, we tested cord blood
mononuclear cells that should be HRV naı̈ve. There were HRV-associated
increases (significant increase compared to mock-infected cells) for one or more
HRVs for IP-10 and IL-15 that was unaffected by addition of PBMCs, for MIP-1a,
MIP-1b, IFN-a, and HGF only with addition of PBMCs, and for ENA-78 only without
addition of PBMCs. All three species B HRVs induced higher levels, compared to A
HRVs, of MIP-1a and MIP-1b with PBMCs and ENA-78 without PBMCs. In contrast,
addition of CBMCs had less effect and did not induce MIP-1a, MIP-1b, or IFN-a nor
block ENA-78 production. Addition of CBMCs did, however, increase IP-10 levels
for HRV 35 and HRV 36 infection. The presence of an effect with PBMCs and no
effect with CBMCs for some responses suggest differences between the two types
of cells possibly because of the presence of HRV memory responses in PBMCs
and not CBMCs or limited response capacity for the immature CBMCs relative to
PBMCs. Thus, our results indicate that different HRV strains can induce different
patterns of cytokines and chemokines; some of these differences may be due to
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differences in memory responses induced by past HRV infections, and other
differences related to virus factors that can inform disease pathogenesis.
Introduction
Human rhinovirus (HRV) is a positive, single stranded RNA virus which belongs
to the genus Enterovirus in the family Picornaviridae. More than 100 genotypes of
HRVs have been identified that are phylogenetically distinct and divisible into
three species, A, B, and C. Ninety percent of species A and B viruses use inter-
cellular adhesion molecule 1 (ICAM1) or CD54 as their receptor [1, 2], whereas
the others use low-density lipoprotein receptor (LDLR). The receptor for species
C HRVs has not yet been identified but is considered to be distinct from those for
species A and B HRVs [3]. HRVs are a primary cause of the common cold and are
frequently associated with exacerbations of asthma and also cause lower
respiratory tract disease including bronchitis, bronchiolitis and pneumonia
[4, 5, 6, 7, 8]. HRV infection of cells triggers cytokine and chemokine production
that may contribute to disease [9, 10, 11, 12, 13, 14, 15, 16]. Since epidemiologic
studies suggest that species B virus is less commonly and species A and C HRVs
are more frequently associated with disease [17, 18, 19, 20, 21, 22, 23, 24], we
wondered if species differences in disease may be accompanied by differences in
induction of cytokines or chemokines.
Several groups have noted differences among HRV serotypes in their in vitro
response to infection. Wark and colleagues [25] measured release of IL-6, IP-10,
IFN-b and IFN-c by HRV-infected primary bronchial epithelial cells and noted
higher levels induced by recent clinical isolates compared to laboratory passaged
strains and differences in levels between cells infected with HRVs from the major
and minor receptor groups. They also noted differences in levels produced by
infected primary bronchial epithelial cells from asthmatic compared to non-
asthmatic patients. We recently reported [26] differences between HRV 14 and
HRV 16 in up or down regulation of several cytokines including those that are
linked to airway inflammation. In these studies, we used a two-chamber trans-well
tissue culture system with a human airway epithelial cell (HAEC) line derived
from an adenocarcinoma of the lung, calu-3 cells, in the lower chamber and
human peripheral blood mononuclear cells (PBMCs) in the upper apical chamber
[26]. This system provides a model of the human local response to HRV infection
and a way to study the effect of differences in HAECs, HRVs or PBMCs on the
response to infection. With this system, we noted differences in cytokines and
chemokines, like FGF-Basic, IL-15, IL-6, IL-28A, ENA-78 and IP-10 without
PBMCs and MIP-1b, IL-28A, MCP-2, and IFN-a with PBMCs between HRV 14
and 16 during infection of calu-3 cells [26].
Since HRV 14 is a species B and HRV 16 a species A virus and both utilize
ICAM-1 receptor, we hypothesized that some of the differences in cytokines and
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chemokines we noted might be associated with one or the other species. Hence to
look into this possibility, we investigated 3 other species A HRV 25, 31 and 36 and
3 other species B viruses HRV 4, 35 and 48 using the two-chamber tissue culture
system. These HRVs are among the many detected in recent studies of acute
respiratory disease, replicate in our tissue culture system, include HRVs using
both receptors, and some, HRV 14, 16, and 48, have been previously described in
studies of the HRV immune response [26, 27, 28, 29], In addition, we also
investigated the response of cord blood mononuclear cells (CBMCs) to HRV
infection and compared these responses to those by adult PBMCs. CBMCs should




Collection of blood for PBMC and CBMC studies was done with written informed
consent and under an Emory University Institutional Review Board approved
protocol (IRB #-00045690 and IRB # 60341) and University of Rochester
approved protocol (# 21058).
PBMCs and CBMCs
Mononuclear cells from the blood of 3 different adult donors and from cord
blood of 3 different infants were purified using ficoll-histopaque density gradient
centrifugation. Briefly, the blood or cord blood was diluted with 2 parts PBS to 1
part blood, layered over Lymphocyte Separation Medium (Cellgro), centrifuged at
800xg for 20min, the buffy coat layer was collected and washed twice in RPMI,
and the mononuclear cells counted, divided into aliquots, and stored in liquid
nitrogen until use. We chose to use cryopreserved cells for this study because they
provide a consistent source of cells and have often been used for these types of
studies.
Human Airway Epithelial Cells (HAEC) and Viruses
Calu-3 cells were obtained from American Type Culture Collection (ATCC) and
grown in minimum essential medium (MEM) supplemented with 10% fetal calf
serum (FCS), 1mM L- Glutamine, 1mM Hepes and 1X non-essential amino acids
(calu-3 media) and incubated at 37 C̊ under 5% CO2. Three species A, HRV 25
(A), HRV 31 (A), and HRV 36 (A) and three species B, HRV 4 (B), HRV 35 (B)
and HRV 48 (B), prototype strains were provided by the Centers for Disease
Control and Prevention (Dr. Dean Erdman). All viruses have been detected in
recent community studies of HRV [22, 27], grow well in our Calu-3/PBMC tissue
culture system and include HRVs representing both receptors groups, i.e. all
species B study viruses and the species A HRV 36 use ICAM1 and the species A
HRV 25 and 31 uses LDLR. HRV 14, 16 and 48 have been described in earlier
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studies of HRV response in human AECs [26, 27, 28, 29]. The viruses were grown
in HeLa cells maintained in MEM containing 10% FCS, 1% penicillin
streptomycin and 1% L-Glutamine at 35 C̊ under 5% CO2. HRV stocks were
prepared by infecting monolayers of HeLa cells. The infected cells were
maintained at 35 C̊ under 5% CO2 until cytopathic effect (CPE) exceeded 70%.
The media was collected and centrifuged briefly to remove the cellular debris.
Virus was purified from the resultant supernatant, by centrifugation through a
20% sucrose cushion gradient at 20,000xg for 2 hours and re-suspending the
pellet in MEM. The purified virus was divided into aliquots and stored at 280 C̊.
To determine the virus titer, Hela cells were grown in 96 well flat bottom tissue
culture plates (5000 cells/well) and infected with 10-fold serial dilutions of virus
in 8 replicates. The infected cells were incubated for 5 days and wells evaluated
daily for CPE by microscopic examination. The tissue culture infectivity dose
(TCID50) of the viruses was calculated based on the 5 day CPE using the Reed
Muench method. Calu-3 cells seeded in 24 well plates were infected with 0.05
MOI of different viruses and supernatants from virus infected wells and control
wells were collected daily to assess levels of viral RNA. The collected media were
briefly centrifuged to remove the cell debris and RNA was extracted using Qiagen
RNeasy mini kit according to manufacturer’s instructions. HRV RNA was assayed
by a real-time RT-PCR assay using One-Step RT-PCR Reagents (Life
Technologies) and the Applied Biosystems 7500 Fast Real-Time PCR System (Life
Technologies Corporation, Carlsbad, CA) as previously described [30].
HAEC and PBMC co-culture
For the co-culture studies, calu-3 cells were seeded and infected with 0.05 MOI of
infectious virus and mock-infected cell control material in duplicate wells. The
inoculum was removed 2 hours later and 500 ml of calu-3 media was added to
each well. The media was removed and fresh media was added one day post
infection (p.i.). One day later, i.e. 2 days p.i., trans-well inserts (polyester trans-
well inserts, 0.33 cm with 0.4 u pores, Corning, Inc., Corning, NY) with one
million live PBMCs (viability determined by trypan blue exclusion) were placed in
the virus infected and control wells. Media was collected from the basolateral
chamber at 6, 24, and 48 hours after addition of the PBMCs. The collected media
was centrifuged, stored at 280 C̊, and later tested by multiplex luminex assays
according to the manufacturer’s instructions for FGF-Basic, IFN-c, IL–12 (p40 /
p70), IL–13, RANTES, MIP–1a, MIG, MIP–1b, VEGF, IL–1b, IL–2, IL–4, IL–5,
IL–6, IL–2R, MCP–1, Eotaxin, IL–8, IL–10, IL–15, IL–17, IL–1RA, GM–CSF, G–
CSF, EGF, HGF, TNF-a, IL–7, IP-10, IFN-a (Human cytokine 30-plex panel, Life
technologies) and ENA-78, MCP-2 and IL-28A (Human cytokine 3 plex panel,
Millipore).
Immune Response to Rhinovirus Infections
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Statistical Analyses
Statistical analyses were conducted using SAS 9.2 (Cary, NC) and statistical
significance was assessed at P,0.05 unless otherwise noted. Due to the small
sample sizes and non-normal data, nonparametric procedures were utilized.
Specifically, for each cytokine, the actual data values were replaced by their rank in
the dataset (i.e., their relative position in the dataset after ordering from least to
greatest) and the analyses were carried out on the ranks of the data. The median
and range were used to summarize cytokine levels. Prior to any modeling, the
Wilcoxen rank sum test was used to identify cytokines that had HRV-associated
responses to one or more HRVs, i.e. levels with HRV-infection were significantly
different from levels with mock-infected control. Cytokines with HRV-associated
responses were then included in the final analyses. Two-factor analysis of variance
models were used to assess the effect of PBMC (yes/no) and species type (A/B/
Control). All models initially included an interaction between PBMC and species
type, but was removed from the model if it was not significant. For models with a
significant interaction, we compared the effect of species on cytokine expression
with and without PBMCs, and the effect of PBMCs on cytokine expression for
each species. For models with a significant interaction, 3 sets of comparisons were
made. The first two sets of comparisons were made among species with and
without PBMCs using 3 planned pairwise comparisons: (1) A vs. Control, (2) B
vs. Control, and (3) A vs. B. The third set of pairwise comparisons examined the
effect of PBMC within each species using 3 additional pairwise comparisons: (1)
A-no PBMC vs. A- with PBMC, (2) B-no PBMC vs. B- with PBMC and (3)
Control-no PBMC vs. Control- with PBMC. To control for multiple comparisons,
a Bonferroni adjustment was used in each set of pairwise comparisons and
statistical significance was assessed using a significance level of 0.05/350.017.
Results
As we and others have noted, different HRVs induce different patterns of secreted
cytokines and chemokines (Table 1). Most of the HRV-associated responses
(significantly different from mock-infected cells, P,0.05 by Wilcoxen rank sum
test) were evident at 24 hours post PBMC addition i.e., 3 days p.i. HRV-associated
response were detected for IFN-a, MIP-1a, MIP-1b, epithelial neutrophil
activation protein-78 (ENA-78), IP-10, IL-15 and HGF (Table 1). There was
variation in the pattern of responses among the HRVs. For example, only HRV 48,
a species B virus, induced a significant increase in IP-10 (P,0.05) and only the 3
species B HRVs showed increases in MIP-1a, MIP-1b and ENA-78 (Table 1). As
we expected, the addition of PBMCs to the infected cells affected results for some
but not all cytokines. For example, the addition of PBMCs to all HRV-infected
cells induced higher levels of IFN-a, HGF and MCP-1 with the exception of HRV
31 for HGF and MCP-1 (Table 1). The increases for IFN-a and HGF resulted in
significant differences (P,0.05) compared to controls but not so for MCP-1. The
addition of PBMCs resulted in a substantial increase in levels of MCP-1 for both
Immune Response to Rhinovirus Infections
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HRV infected and mock infected cells resulting in no HRV-associated increase.
There was a suggestion of an increase in MCP-1 levels after addition of PBMCs for
individual species B HRVs (P50.051 to 0.084)) but did not achieve significance.
The change in cytokine or chemokine levels after the addition of PBMCs for a
given HRV was comparable for all 3 donor PBMCs.
Interestingly, species associated significant differences in responses (significant
difference between values for all group A compared to values for all group B
HRVs) were evident for MIP-1a, MIP-1b and MCP-1 after the addition of
PBMCs and ENA-78 without PBMCs (Fig. 1A, 1B, 1C and 1D). For MIP-1a,
MIP-1b and MCP-1, species B HRVs showed a significant HRV-associated
response after the addition of PBMCs (p,0.001), species A HRVs did induce an
HRV-associated response and, with the addition of PBMCs, levels for HRV species
B were significantly higher than those for HRV species A (p,0.001). Without
PBMCs, HRV species B expressed higher levels of ENA-78 compared to species A
and controls (p,0.001). The addition of PBMCs significantly decreased ENA-78
expression in HRV species B (p,0.001), had no effect on ENA-78 expression for
species A and mock infected control cells, and eliminated the difference in levels
between HRV species A and B and mock infected cells (Fig. 1C).
Next, to determine if memory responses induced by prior HRV infection might
contribute to responses we detected, we tested CBMCs from 3 infants. For CBMC
experiments, we included the previously tested HRV 16 (species A) and HRV 14
(species B) viruses [26] with the 6 HRVs in the present study. Though the CBMCs
did increase the magnitude of MCP-1 and INF-a, the increase was similar for
infected and mock-infected cells and consequently did not change the pattern in
Table 1. HRV-associated responses in calu-3 cells with or without PBMCs.
PBMC Virus MIP-1a MIP-1b MCP-1 ENA-78 IP-10 IFN-a HGF IL-15
No HRV 25 58 42 376 20840 155 43 70 217*
HRV 31 58 47 321 20230 75* 45 51 163
HRV 36 66 53 333 21868 131 50 59 215
HRV 4 50 42 288 43487* 103 38 52 147
HRV 35 67 42 348 62448* 119 24 44 181*
HRV 48 58 51 266 46628* 500* 54 122 205*
Control 66 49 408 24423 140 43 21 95
Yes HRV 25 76 116 10697 29776 127* 229* 158* 216*
HRV 31 62 70 8978 23703 67 227* 113 147
HRV 36 55 84 18180 20000* 64 209* 126* 166
HRV 4 181* 254* 22378 29705 53 222* 177* 181
HRV 35 184* 254* 18614 28132 76 242* 132* 144
HRV 48 255* 340* 19696 23049 434* 245* 186* 181
Control 69 83 8572 29968 86 62 43 109
Shown are the median values of cytokines and chemokines (pg/ml) produced in response to various HRVs and uninfected control infections at 24 hours
after the time inserts with PBMCs were added (n53). Significant differences in cytokine/chemokine levels for HRV infected cells when compared to
uninfected controls were calculated using Wilcoxen rank sum tests. * indicates significantly different from control (p,0.05).
doi:10.1371/journal.pone.0114322.t001
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HRV-associated responses seen without CBMCs (Table 2) with 3 exceptions. The
addition of CBMCs to HRV 36 and HRV 35 did give an HRV-associated increase
in IP-10 levels not seen with PBMCs (Table 2) and, though the addition of
CBMCs to HRV 36- and 31-infected cells did not significantly change ENA 78
levels, it was associated with a lower level for mock-infected cells resulting in an
HRV-associated responses, significantly different from mock infected cells, not
seen with PBMCs. Finally, we compared the levels of cytokines/chemokines
secreted with PBMCs to that with CBMCs exposed to HRV infected cells. Table 3
shows significant differences in up regulation or down regulation of certain
cytokines and chemokines with PBMCs or CBMCs associated with different
HRVs. MIP-1a and IFN-a levels were significantly higher (p,0.05) with some
strains of HRV after PBMC exposure but not after CBMC exposure (Table 3). In
contrast, ENA-78 levels with species B viruses were suppressed with addition of
PBMCs but not with the addition of CBMCs. Consequently, ENA-78 levels were
significantly lower (p,0.05) for species B virus infected cells with the addition of
PBMCs compared to those with the addition of CBMCs (Table 3).
Fig. 1. HRV species associated cytokine/chemokine production in calu-3 cells. Fig. 1A, 1B, 1C and 1D. Levels of cytokines/chemokines (pg/ml) in
the supernatant of calu-3 cells infected with species A (HRV 25, HRV 31 and HRV 36) or species B (HRV 4, HRV 35 and HRV 48) HRVs and
uninfected control cells with or without PBMCs. Data are mean from duplicate infection using three PBMC donors (n53).
doi:10.1371/journal.pone.0114322.g001
Immune Response to Rhinovirus Infections
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Table 2. HRV-associated responses in calu-3 cells with or without CBMCs.
CBMC Virus MIP-1a MIP-1b MCP-1 ENA-78 IP-10 IFN-a HGF IL-15
No HRV 25 40* 44 654 35021 159 31 98 236*
HRV 31 39 37 506 31285 151 23 92 125*
HRV 36 38 35 439 33890 170 24 153 51
HRV 16 37 35 533 41130* 304* 24 82 30
HRV 4 38 34 533 59513* 149 24 87 49
HRV 35 36 32 365 58043* 145 24 92 48
HRV 48 38 34 351 53813* 447* 27 101 149*
HRV 14 29 34 269 58555* 1158* 19 62 54
Control 33 33 416 29125 153 41 62 48
Yes HRV 25 56 75 3737 32616 435 157 101 169
HRV 31 44 67 3113 35991* 137 119 92 107
HRV 36 79 77 3456 31344* 474* 169 132 162
HRV 16 64 67 4688 36628* 855* 193 92 70
HRV 4 53 49 5837 58390* 361 191 131 206
HRV 35 54 60 4146 56605* 404* 136 72 107
HRV 48 69 65 2541 47299* 736* 158 82 170
HRV 14 174 456 3675 57335* 644* 201 92 147
Control 91 56 4002 21868 208 188 101 90
Shown are the median values of cytokines and chemokines (pg/ml) produced in response to various HRVs and uninfected control infections at 24 hours
after the time inserts with CBMCs were added (n53). Significant differences in cytokine/chemokine levels for HRV infected cells when compared to
uninfected controls were calculated using Wilcoxen rank sum tests. * indicates significantly different from control (p,0.05).
doi:10.1371/journal.pone.0114322.t002
Table 3. Comparison of CBMC vs. PBMC.
Group Virus MIP-1a MIP-1b MCP-1 ENA-78 IP-10 IFN-a HGF IL-15
PBMC HRV 25 76 116 10697 29776 127 229 158 216
HRV 31 62 70 8978 23703 67 227* 113 147
HRV 36 55 84 18180 20000* 64* 209 126 166
HRV 4 181 254 22378* 29705* 53* 222 177 181
HRV 35 184* 254 18614* 28132* 76* 242 132 144
HRV 48 255* 340 19696* 23049* 434 245* 186 181
Control 66 49 408 24423 86* 62 43 109
CBMC HRV 25 56 75 3737 32616 435 157 101 169
HRV 31 44 67 3113 35991 137 119 92 107
HRV 36 79 77 3456 31344 474 169 132 162
HRV 4 53 49 5837 58390 361 191 131 206
HRV 35 54 60 4146 56605 404 136 72 107
HRV 48 69 65 2541 47299 736 158 82 170
Control 33 33 416 29125 153 41 62 48
Comparison of HRV-associated response in calu-3 cells with CBMCs and PBMCs. Shown are the median values of cytokines and chemokines (pg/ml)
produced in response to various HRVs and uninfected control infections at 24 hours after the time inserts with PBMCs or CBMCs were added (n53).
Significant differences in cytokine/chemokine levels for HRV infected cells comparing CBMCs and PBMCs were calculated using Wilcoxen rank sum tests.
* indicates significantly different in values with CBMCs compared to those with PBMCs (p,0.05).
doi:10.1371/journal.pone.0114322.t003
Immune Response to Rhinovirus Infections
PLOS ONE | DOI:10.1371/journal.pone.0114322 December 12, 2014 8 / 14
We also determined the replication of the viruses using RT PCR method
(Fig. 2). Different HRVs have different replication capabilities and it is possible
that differences in virus replication caused some of the cytokine and chemokine
differences we saw. As shown in Fig. 2, species B HRVs replicated better than
species A HRVs.
Discussion
Epidemiologic studies suggest the three HRV species, A, B and C, have differences
in illness patterns. For example in some studies, species A and C HRVs have
stronger associations with exacerbations of asthma and acute respiratory illness
than species B HRVs [17, 18, 19, 20, 21, 22, 23, 24]. These epidemiologic observa-
tions and our recent finding [26] that HRV 14 (a group B virus) and HRV 16 (a
group A virus) infection of calu-3 cells with PBMCs induce different cytokine and
chemokine responses led us to look for strain and species differences in responses
induced by in vitro HRV infection. We hypothesized that HRV strain or species
differences in disease might be associated with and possibly explained by species
differences in cytokine and chemokine responses detected by our in vitro model.
Previously we and others have shown that a variety of cytokines and chemokines
were induced by both HRV 14 and/or HRV 16 infection in vitro that include FGF-
Fig. 2. Time course of replication in HRV infected Calu-3 cells. Calu-3 cells were infected with serial
dilutions of viruses in 8 replicates and infectious virus TCID50 in cell supernatant was determined in a
microneutrlization assay and calculated using Reed Muench method.
doi:10.1371/journal.pone.0114322.g002
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Basic, chemokines and cytokines like IL-6, IL-15, MCP-2, IP-10, MIP-1b, type I
IFN-a, type III IFN-l2 (IL-28A), and ENA-78 [26, 31, 32]. Several groups have
also studied cytokine or chemokine responses during HRV infection in respiratory
specimens from patients with and without asthma. Gern et al reported that
inoculation of allergic individuals with HRV led to increases in cytokine levels in
respiratory secretions including IL-8 and granulocyte colony stimulating factor
(GCSF) that was associated with increased neutrophils in sputum [33]. Miller et al
detected an association between increased levels of Type III IFN-l and wheezing
in asthmatic patients with HRV infection [34]. The cytokines and chemokines
induced by HRV infection are associated with a range of functions including
activation of immune cells that are implicated in allergic responses, cell
proliferation, anti-viral activity, and pro-inflammatory and anti-inflammatory
functions [35]. In the present study, we describe the cytokine and chemokine
responses seen with 3 species A viruses, HRV 25, HRV 31 and HRV 36, and 3
species B viruses, HRV 4, HRV 35 and HRV 48, and differences in induction of
cytokines and chemokines including some that are common to HRVs from one
but not the other species.
Although we analyzed a variety of cytokines and chemokines that are associated
with HRV infection, we detected only a few which are significantly higher than
uninfected controls and associated with HRV infection. Most of the cytokines and
chemokines in mock infected control wells showed similar levels to HRV infected
cells. We found increases in IP-10, IL-15, IFN-a, HGF, MIP-1a, MIP-1b, and
ENA-78 with some or all of the HRVs. For IL-15, IP-10, HGF and ENA-78 the
increase occurred without PBMCs while the increase only was noted with PBMCs
for IFN-a, MIP-1a, and MIP-1b. Increases for IFN-a and HGF were noted for all
6 viruses (excluding HRV 31 for HGF) while increases for MIP-1a, MIP-1b,
MCP-1 and ENA-78 were only seen with the HRV species B. Findings from our
earlier study support species differences in induction of MIP-1b and ENA-78 [26]
but not for MIP-1a. In that study, the species B HRV, HRV 14, showed significant
HRV-associated increases in MIP-1b and ENA-78 while the species A HRV, HRV
16, did not and neither showed a significant HRV-associated increase in MIP-1a.
As in the present study, our earlier study showed HRV-associated increase in
ENA-78 for the group B virus was only evident without PBMCs. PBMCs down
regulated the ENA-78 response to levels similar to that induced by the group A
HRV- and mock-infected A549 cells. ENA-78 has been reported to be induced by
HRV infection of BEAS-2B cells and suggested to have a role in allergy and airway
inflammation [36, 37]. A possible mechanism for the decrease in levels of some
cytokine and chemokines after the addition of PBMCs is suggested by reports
showing that PBMCs can induce receptor mediated consumption of cytokines or
release mediators that regulates cytokine or chemokine degradation [38, 39]. In
contrast to ENA-78, the increase in MIP-1a and MIP-1b for species B but not
species A HRV was only present after the addition of PBMCs. Thus, the combined
results from the earlier and the present study suggest species specific responses for
MIP-1b and ENA-78.
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Most of the in vitro studies on the response of human immune cells to HRV
infection have used adult PBMCs. Since adults will have already been infected
with multiple HRVs, it is possible that memory responses induced by these
previous infections might have contributed to some of our findings. Since there is
cross reactivity among serotypes [40, 41, 42], previous infections by the same or
heterologous serotypes might lead to such memory responses. Our findings that
CBMCs, which are likely HRV naïve, usually had less effect on HRV-associated
responses suggest that differences in HRV memory might have contributed to
some of the differences we saw. The difference between CBMC- and PBMC-
associated responses might also result from differences in their ability to respond
to HRV infection. The immune system of the fetus and young infant is immature,
and therefore CBMCs may be inherently less able to respond to HRV infection.
Weitzel et al., reported differences in the expression of microRNAs derived from
adults and neonates that regulate the transcription of cytokine genes [43, 44]. We
did note some differences in levels of cytokines and chemokines but, in most
instances, changes were similar for HRV-infected and uninfected cells and, thus,
the addition of CBMCs, unlike the addition of PBMCs, usually did not change the
pattern of HRV-associated responses. Previously, lower levels of MCP-1 and IL-
1Ra were associated with increased severity of HRV infection [45] and a new
report showed that MCP-1 production by epithelial cells and macrophages
contributes to HRV-induced airway hyper responsiveness and inflammation in a
mouse model of allergic airways disease [46]. In our study, HRV infection did not
lead to a significant increase in MCP-1 levels though we noticed that species B
viruses induced higher levels than species A viruses. In addition, previously
studied HRV 14 and HRV 16 utilize the same receptor, ICAM1. However, two of
the species A viruses HRV 25 and 31 in this study use the minor LDLR allowing
comparisons across species and receptor usage. We did not note any receptor-
associated differences in responses. Differences in cytokine and chemokine
production detected with this model of the host response to HRV infection system
should provide a way to explore the effect of virus and host differences on HRV
disease.
In conclusion, the results of this study show serotype differences in the cytokine
and chemokine responses to infection with our in vitro model and some of these
differences may be species A or B specific. The differences that we noticed between
PBMCs and CBMCs emphasize the need to recognize the potential that memory
responses and/or maturity of immune cells need to be considered in interpreting
results. This model system of the host response to HRV infection applied to HRVs
and PBMCs linked to different disease outcomes should help clarify viral and host
factors that contribute to HRV disease.
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